SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow declines year over year

Q3 FY2026 free cash flow of $5.94M (cash outflow) fell 16.0% year over year, behind the -10.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 21.7% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Free cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -16.0% toward the trailing-twelve-month pace of -10.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$5.94M-21.7% QoQ
Last fiscal yearDec 2025
-$28.39M-19.8% YoY
LTMSep 2026
-$27.3M-10.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.0%——
1 year-19.8%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(28.39M) USD
Year-over-year change
+19.8%

Free Cash Flow vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.9% is the 8th highest of 11, against a peer median of +15.9%.
  • Over three fiscal years its annual growth of +0.1% compares with a peer median of +12.7%.
SLS Competitors
Free Cash Flow for SLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.92B USD+100.4%+14.9%33.0%
AAPGAscentage Pharma Group InternationalFY2025CN¥1.2B CNY+785.9%+10.5%215.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$369.81M USD+253.2%+15.3%52.7%
IMNMImmunome, Inc.LTM Sep 2026$238.7M USD+24.3%+90.7%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$148.43M USD-8786.2%+15.9%1249.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$134.47M USD+12.4%+54.4%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$96.02M USD+19.3%-3.8%275.4%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$87.93M USD-67.2%-6.8%39.0%
MGNXMacroGenics, Inc.LTM Mar 2026$71.69M USD-1.0%-2.9%45.6%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$43.78M USD-58.6%-13.4%261.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$27.3M USD-10.9%+0.1%—
Peer median (excluding SLS) —+15.9%+12.7%133.9%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Depreciation & Amortization1.27M457K37.87M31.51M0
Deferred Income Tax(239K)(457K)000
Stock-Based Compensation1.01M1.73M1.39M1.56M1.96M
Change in Working Capital(7.62M)5.64M3.35M(6.65M)(4.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables(2.51M)1.21M2.3M(2.14M)(535K)
Other Working Capital(5.1M)4.43M1.04M(4.51M)(3.54M)
Other Non-Cash Items248K10.13M(36.67M)(30.95M)597K
Operating Cash Flow(26.02M)(23.81M)(31.41M)(35.4M)(28.39M)
Capital Expenditures0(4.5M)(5.5M)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(4.5M)(5.5M)00
Debt Repayment00000
Common Stock Issued9.01M23.99M22.23M46.16M86.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.07M85K90K594K(527K)
Financing Cash Flow12.07M24.08M22.32M46.76M86.3M
Effect of Forex Changes00000
Net Change in Cash(13.95M)(4.23M)(14.6M)11.36M57.91M
Free Cash Flow(26.02M)(28.31M)(36.91M)(35.4M)(28.39M)

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.